Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Symptoms of RA for no more than 12 months prior to enrollment * Meet American College of Rheumatology/European League against Rheumatism (ACR/EULAR) 2010 criteria for classification of RA * Treated with Methotrexate (MTX) for at least 12 weeks prior to randomization with a stable oral dose for at least 4 weeks, Subjects must randomize on the maximum tolerated dose of oral methotrexate (minimum of 15 mg and maximum of 25 mg per week), dose of MTX \< 15 mg/week but ≥ 7.5 mg/week is permitted if subjects are intolerant to higher doses * At least 3 tender \& 3 swollen joints * Anti-cyclic citrullinated peptide (CCP) \> 3X the upper limit of normal and positive rheumatoid factor Exclusion Criteria: * History of other autoimmune diseases (eg, psoriasis, systemic lupus, erythematosus, etc) * Prior use of non-biologic therapy other than methotrexate * Prior use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARD) therapy * Subjects with chronic or recent acute serious infection Other protocol defined inclusion/exclusion criteria could apply